Sugi Predict

Sugi Predict / Compounds / SCHEMBL4595441

SCHEMBL4595441

SCHEMBL4595441

NC=CCn1ccc(N)nc1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 4/20 0.41
▸ SLC22A6 Q4U2R8 1/20 0.40
▸ PDE3A Q14432 3/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ SLC29A1 Q99808 1/20 0.35
▸ LMNA P02545 3/20 0.35
▸ THRB P10828 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ MDM2 Q00987 1/20 0.35
▸ NCOA1 Q15788 1/20 0.35
▸ NCOA3 Q9Y6Q9 1/20 0.35
▸ EP300 Q09472 9/20 0.34
▸ CACNA1F O60840 2/20 0.33
▸ ALB P02768 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ CACNA1D Q01668 2/20 0.33
▸ CACNA1S Q13698 2/20 0.33
▸ CACNA1C Q13936 2/20 0.33
▸ CYP2D6 P10635 1/20 0.31
▸ DNMT1 P26358 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29138425 0.82 FGFR1 (0.43) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL278549 0.81 SLC2A1 (0.46) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL16446911 0.77 FGFR1 (0.47) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL1732488 0.76 FGFR1 (0.48) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL1733201 0.76 FGFR1 (0.48) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL11374629 0.76 FGFR1 (0.48) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL20919715 0.76 FGFR1 (0.46) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL3680116 0.75 FGFR1 (0.52) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL11304135 0.74 FGFR1 (0.44) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL24709494 0.74 FGFR1 (0.44) FGFR1SLC22A6PDE3APDE4DSLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111430-A1 CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL PRIME MEDICINE, INC. (US) 2025-05-30 — — WO claimed
WO-2025043082-A2 COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS THE BROAD INSTITUTE, INC. (US) 2025-02-27 — — WO claimed
WO-2025038970-A1 MODIFIED OLIGONUCLEOTIDES CONTAINING MULTIPLE OLIGONUCLEOTIDES ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
WO-2025038963-A1 OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
WO-2025038971-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
WO-2025038960-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
EP-4466074-A1 POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF The Broad Institute Inc. (US) 2024-11-27 — — EP claimed
US-20240277872-A1 MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2024-08-22 — — US claimed
US-20240229109-A1 METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS MODERNATX, INC. (US) 2024-07-11 — — US claimed
EP-4337331-A1 MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF The Broad Institute Inc. (US) 2024-03-20 — — EP claimed
EP-4314332-A2 METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS ModernaTX, Inc. (US) 2024-02-07 — — EP claimed
WO-2023141474-A9 POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-10-26 — — WO claimed
WO-2023141474-A1 POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-07-27 — — WO claimed
WO-2022241045-A1 MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2022-11-17 — — WO claimed
WO-2022212711-A2 METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS MODERNATX, INC. (US) 2022-10-06 — — WO claimed
EP-4737574-A2 POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF The Broad Institute Inc. (US) 2026-05-06 — — EP disclosed
EP-4573215-B1 CELL-FREE METHOD OF PRODUCING SYNTHETIC CIRCULAR NUCLEIC ACID ALDEVRON L L C (US) 2026-04-29 — — EP disclosed
EP-1934376-A2 DNA MICROARRAY FOR RAPID IDENTIFICATION OF CANDIDA ALBICANS IN BLOOD CULTURES. UNIVERSITÄT ZU KÖLN (DE) 2008-06-25 — — EP disclosed
WO-2007039319-A2 DNA MICROARRAY FOR RAPID IDENTIFICATION OF CANDIDA ALBICANS IN BLOOD CULTURES UNIV KOELN (DE) 2007-04-12 — — WO disclosed
EP-1770171-A1 DNA microarray for rapid identification of Candida albicans in blood cultures. UNIVERSITÄT ZU KÖLN (DE) 2007-04-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277872-A1 MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF NSUN3, NSUN2, RNGTT FGFR1 3962/4885SLC22A6 4215/4885PDE3A 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.